Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
0.4250
-0.0074 (-1.71%)
Jun 20, 2025, 11:12 AM - Market open

Impact BioMedical Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
-25.01-24.71-4.34-7.05-1.3-0.81
Upgrade
Depreciation & Amortization
0.010.010.01---
Upgrade
Other Amortization
1.121.111.111.111.11-
Upgrade
Asset Writedown & Restructuring Costs
25.3625.36----
Upgrade
Loss (Gain) From Sale of Investments
---4.1--
Upgrade
Stock-Based Compensation
0.050.02----
Upgrade
Other Operating Activities
-5.03-5.1-0.07-0.83-1.94-0.08
Upgrade
Change in Accounts Receivable
0.130.13-0.13---
Upgrade
Change in Accounts Payable
-0.73-0.440.290.420.110
Upgrade
Change in Other Net Operating Assets
-0.01-0.30.27-0-0-0
Upgrade
Operating Cash Flow
-4.12-3.92-2.85-2.24-2.03-0.9
Upgrade
Capital Expenditures
---0.02-0.28--
Upgrade
Investment in Securities
----0.07-4.18-0.63
Upgrade
Other Investing Activities
000-0.01-5.28-
Upgrade
Investing Cash Flow
00-0.02-0.35-9.46-0.63
Upgrade
Short-Term Debt Issued
---2.5511.461.06
Upgrade
Long-Term Debt Issued
-2.192.87---
Upgrade
Total Debt Issued
1.712.192.872.5511.461.06
Upgrade
Net Debt Issued (Repaid)
1.712.192.872.5511.461.06
Upgrade
Issuance of Common Stock
3.733.73---0.44
Upgrade
Financing Cash Flow
5.435.922.872.5511.461.49
Upgrade
Miscellaneous Cash Flow Adjustments
-----0-
Upgrade
Net Cash Flow
1.322-0-0.04-0.03-0.04
Upgrade
Free Cash Flow
-4.12-3.92-2.87-2.52-2.03-0.9
Upgrade
Free Cash Flow Margin
----5036.00%--
Upgrade
Free Cash Flow Per Share
-0.36-0.36-0.05-0.04-0.03-0.01
Upgrade
Levered Free Cash Flow
-2.59-1.92-1.44-0.98-1.16-0.56
Upgrade
Unlevered Free Cash Flow
-1.9-1.26-1.17-0.69-0.97-0.56
Upgrade
Change in Net Working Capital
0.770.27-0.25-0.60.090
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q